Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital
Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10 mg/kg based on total body weight but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750 mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 66(2022), 1 vom: 18. Jan., Seite e0160321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diggs, Fernando J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aminoglycosides |
|---|
| Anmerkungen: |
Date Completed 22.03.2022 Date Revised 19.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01603-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332024849 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332024849 | ||
| 003 | DE-627 | ||
| 005 | 20231225214739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01603-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM332024849 | ||
| 035 | |a (NLM)34662182 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diggs, Fernando J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2022 | ||
| 500 | |a Date Revised 19.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10 mg/kg based on total body weight but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750 mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a capped dosing | |
| 650 | 4 | |a telavancin | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Lipoglycopeptides |2 NLM | |
| 650 | 7 | |a telavancin |2 NLM | |
| 650 | 7 | |a XK134822Z0 |2 NLM | |
| 700 | 1 | |a Edwards, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Garza, Kimberly B |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Ali A M |e verfasserin |4 aut | |
| 700 | 1 | |a Durham, Spencer H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 66(2022), 1 vom: 18. Jan., Seite e0160321 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2022 |g number:1 |g day:18 |g month:01 |g pages:e0160321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01603-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2022 |e 1 |b 18 |c 01 |h e0160321 | ||